CD274 and neoplasm: Some have attributed the difference in trial outcomes data to criteria limiting the patients in the pembrolizumab study to only those with high tumor expression of PD-L1 (>50%) versus the nivolumab trial, which accepted a less stringent population (>5% PD-L1 expression) (48, 49).